Equities
Health CareMedical Equipment and Services
  • Price (USD)120.66
  • Today's Change0.21 / 0.17%
  • Shares traded36.00
  • 1 Year change-4.07%
  • Beta1.2204
Data delayed at least 15 minutes, as of Jul 02 2025 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. Life Sciences and Diagnostics Markets segment comprises seven areas of activity. It offers active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables. Agilent CrossLab segment offers a services and consumables portfolio that spans the entire lab, in addition to software and laboratory automation solutions, which are designed to enhance customer outcomes. Applied Markets segment offers application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products.

  • Revenue in USD (TTM)6.63bn
  • Net income in USD1.17bn
  • Incorporated1999
  • Employees18.00k
  • Location
    Agilent Technologies Inc5301 Stevens Creek BlvdSANTA CLARA 95051United StatesUSA
  • Phone+1 (408) 345-8886
  • Fax+1 (408) 345-8474
  • Websitehttps://www.agilent.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
A:NYQ since
announced
Transaction
value
Sigsense Technologies IncDeal completed29 Jul 202429 Jul 2024Deal completed-12.13%--
BioVectra IncDeal completed22 Jul 202422 Jul 2024Deal completed-8.44%925.00m
Data delayed at least 15 minutes, as of Jul 02 2025 21:00 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Zimmer Biomet Holdings Inc7.70bn913.40m18.50bn17.00k20.721.499.602.404.514.5138.0662.630.35290.96225.17452,852.904.192.344.752.6871.0571.1811.887.601.466.460.366537.523.85-0.7725-11.742.05-3.690.00
Waters Corp2.98bn657.02m20.94bn7.60k31.9410.6724.617.0211.0211.0250.0432.980.65562.314.45392,533.3014.4418.4118.0223.4659.2758.7122.0222.811.2813.770.4260.000.06674.22-0.68511.61-2.75--
Insulet Corp2.20bn402.20m21.22bn3.90k54.2815.9543.689.655.565.5629.7218.910.71611.496.08563,820.5013.106.0015.507.0370.3967.0518.299.223.6349.390.56030.0022.0722.92102.76104.84-4.75--
Steris PLC5.46bn610.12m23.44bn17.79k38.683.5521.554.296.166.2055.1167.180.51484.875.32306,938.505.775.046.365.5144.0143.7511.2010.691.3912.760.23637.516.2412.4910.648.4011.528.99
DexCom Inc4.15bn535.20m32.77bn10.30k64.0914.4643.107.901.301.3010.115.780.62692.893.89402,718.408.098.7912.4411.7560.7264.9712.9014.901.32--0.52460.0011.3422.276.4141.6314.79--
Agilent Technologies Inc6.63bn1.17bn34.28bn18.00k29.705.5823.755.174.064.0623.0921.610.5763.085.07370,279.3010.1310.9312.2513.0953.7753.3517.5917.931.6024.950.362921.83-4.734.753.953.7719.367.80
GE HealthCare Technologies Inc19.80bn2.18bn34.85bn53.00k16.013.7912.361.764.764.7643.1320.070.60185.544.51373,547.206.84--9.67--41.9940.3511.3710.780.76018.180.4831.190.61383.4143.483.823.91--
Resmed Inc5.02bn1.31bn37.52bn9.98k28.736.7624.677.478.918.9134.0537.830.69832.455.65503,159.2018.2614.2420.7316.5358.7656.8526.1520.352.4958.860.108232.6210.9512.4413.7519.988.235.89
IDEXX Laboratories Inc3.93bn894.97m43.65bn11.00k50.1530.2642.4111.1010.8210.8247.5317.931.203.876.81357,439.6027.2628.1140.0142.1561.2859.5622.7622.190.811153.370.39370.006.4610.125.0715.73-3.35--
Edwards Lifesciences Corp5.54bn1.44bn45.18bn15.80k31.784.4628.628.162.427.009.3117.280.48670.9847.45350,557.0012.6314.5214.2816.6179.3879.0125.9525.543.66--0.05540.008.574.5814.555.940.2857--
Veeva Systems Inc2.86bn780.66m46.18bn7.29k59.957.4256.2316.174.714.7117.2538.110.4093--6.06391,622.1011.1911.3313.8514.3575.5072.6027.3423.96----0.000.0016.2019.9935.8418.8536.56--
Becton Dickinson and Co20.87bn1.50bn50.81bn74.00k34.332.0113.142.435.165.1671.9688.070.38423.327.47281,986.502.762.553.202.9244.6845.307.187.290.64277.180.432976.934.163.1415.9910.56-5.404.29
Data as of Jul 02 2025. Currency figures normalised to Agilent Technologies Inc's reporting currency: US Dollar USD

Institutional shareholders

37.70%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Mar 202532.09m11.25%
BlackRock Fund Advisorsas of 31 Mar 202515.37m5.39%
SSgA Funds Management, Inc.as of 31 Mar 202512.61m4.42%
Massachusetts Financial Services Co.as of 31 Mar 202510.06m3.53%
Wellington Management Co. LLPas of 31 Mar 20258.11m2.84%
T. Rowe Price Investment Management, Inc.as of 31 Mar 20257.60m2.66%
Geode Capital Management LLCas of 31 Mar 20257.20m2.53%
Pictet Asset Management SAas of 31 Mar 20255.34m1.87%
Generation Investment Management LLPas of 31 Mar 20254.98m1.75%
BlackRock Investment Management (UK) Ltd.as of 31 Mar 20254.18m1.46%
More ▼
Data from 31 Mar 2025 - 31 Mar 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.